Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Further evidence for action mechanism was provided by assays
2024-11-19

Further evidence for action mechanism was provided by assays using [3H]nisoxetine, a selective NET inhibitor used as standard radioligand for competitive binding experiments. The results showed dose-dependent blocking of [3H]nisoxetine binding by both xylazine and dexmedetomidine. Nisoxetine binds t
-
The presence of different LO
2024-11-19

The presence of different 5-LO splice variants was first demonstrated in human phosphodiesterase inhibitors tumour cells and in dimethyl sulfoxide-differentiated HL-60 cells [40] and a correlation between the 5-LO splicing pattern and the malignancy of the brain tumours was found. Later, other spli
-
Aurora A and B are required for the control of
2024-11-19

Aurora A and B are required for the control of mitosis whereas Aurora C is mainly invoved in meiosis (Goldenson and Crispino, 2015). Interestingly, Aurora B is partnered with inner centromere protein (INCENP), survivin and Borealin to form a chromosomal passenger complex (CPC) that is critical for t
-
RS 127445 HCl synthesis Consistent with a damaging role for
2024-11-19

Consistent with a damaging role for increased 12/15-LOX activity in stroke, systemic administration of the 12/15-LOX inhibitor, LB1, 2 h after permanent focal cerebral ischemia significantly reduced infarct size 24 h after the ischemia, and the treatment group demonstrated improved behavioral and he
-
br Concluding remarks br Definition Prion diseases are fatal
2024-11-19

Concluding remarks Definition Prion diseases are fatal neurodegenerative disorders that are caused by an unconventional agent that is neither bacterial nor viral, but is in essence an infectious misfolded amyloidogenic protein, termed a prion (Prusiner, 1982). Once considered highly controvers
-
br Conclusions br Funding This work was supported by
2024-11-19

Conclusions Funding This work was supported by a Finnish government subsidy for health science research [grant numbers TYH2012141, TYH 2013218, and TYH 2014216]; the SSAC Foundation [grant numbers SLS-504141 and SLS-693781]; and the Paulo Foundation. The funding sources had no involvement in s
-
The excellent safety profile of solanezumab
2024-11-18

The excellent safety profile of solanezumab and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The A4 study (NCT02008357) started in Febr
-
Most of the modifications in the sympathetic
2024-11-18

Most of the modifications in the sympathetic nervous system occurring with aging, including decreased βAR responsiveness, increased circulating catecholamines, and overall hyposensitivity to adrenergic stress, are also observed in patients with failing hearts. Moreover, young people are more reactiv
-
While HTPCs are not immune
2024-11-18

While HTPCs are not immune cells, they produce IL-6, MCP-1 and other immunologically relevant factors (Mayer et al., 2016). Our results demonstrated that epinephrine and phenylephrine increased the mRNA expression levels of COX-2, IL-6 and MCP-1 in HTPCs without affecting the mRNA expression level o
-
To investigate further the clinical
2024-11-18

To investigate further the clinical and mutational spectrum associated with -related dyskinesia, we here performed a screen in a large series of patients affected with an unexplained hyperkinetic movement disorder, resulting in the identification of 2 pediatric patients presenting with a novel pheno
-
ACK can be localized to clathrin coated vesicles The
2024-11-18

ACK1 can be localized to clathrin-coated vesicles [1]. The association of SNX9 with synaptojanin-1 would suggest the two cooperate during endocytosis at the synapse by coupling the sorting nexin to changes in phospholipid composition. ACK1 in turn negatively regulates the association of SNX9 with ta
-
br Co http www apexbt com media
2024-11-18

Conclusions This paper is the first meta-analysis about the association between SRD5A2 V89L polymorphism and hypospadias risk. The results of this meta-analysis have revealed that V89L polymorphism definitely increases the risk of hypospadias, and the C allele is a genetic risk factor for hypospa
-
br Funding br Introduction The interest in the
2024-11-18

Funding Introduction The interest in the effects of endocrine disrupting chemicals (EDCs) in the aquatic environment continues to increase over the past decade, specifically those that act on steroidogenic pathways. EDCs that include synthetic androgenic and estrogenic compounds can severely a
-
The present study indicates elevated ATX
2024-11-18

The present study indicates elevated ATX activity as a highly sensitive and specific biomarker to differentiate ICP from other pregnancy-related liver disorders or pruritic dermatoses. In BLU9931 receptor to the current gold standard for diagnosis, total fasting serum bile salt levels, ATX appeared
-
br Regulatory mechanisms of ASK
2024-11-18

Regulatory mechanisms of ASK1 activity The functions of ASK1 in disease ASK1 inhibitor As mentioned above, ASK1 plays a pivotal role in the pathogenesis of various diseases; hence, an ASK1 inhibitor has therapeutic potential. Although inhibitors of the ASK1 downstream kinases p38 and JNK ar
15896 records 58/1060 page Previous Next First page 上5页 5657585960 下5页 Last page